Metronidazole: Nursing Drug Guide, Alcohol Interaction & NCLEX Review
Anaerobic and protozoal coverage depends on nurses enforcing strict alcohol and propylene glycol abstinence during therapy and for at least three days after the last dose—plus early recognition of disulfiram-like reactions and CNS toxicity (peripheral neuropathy, ataxia, seizures) that can persist if dosing continues.
Oral metronidazole causes a disulfiram-like reaction with alcohol or propylene glycol (abdominal cramps, nausea, vomiting, headache, flushing)—avoid alcohol and propylene glycol during therapy and for at least three days after the last dose per FLAGYL labeling. Do not give metronidazole to patients who used disulfiram within the last two weeks. Labeling also warns of encephalopathy, peripheral neuropathy, seizures, and serious skin reactions; persistent neurologic symptoms demand immediate drug discontinuation and prescriber escalation. Metronidazole is contraindicated in Cockayne syndrome (fatal hepatotoxicity reported) and in first-trimester trichomoniasis.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every dose: confirm no alcohol or propylene glycol exposure, no recent disulfiram, and no new numbness, ataxia, or seizure activity. Teach strict abstinence through therapy plus three days after the last dose. Complete the full antibacterial course when ordered—do not restart after neurologic red flags without prescriber clearance.
Most common brand names
Metronidazole is supplied as oral tablets and capsules, oral suspension, intravenous infusion, and topical gel or cream depending on indication. Verify strength and route on the MAR—anaerobic systemic therapy is not interchangeable with topical rosacea or vaginal gel products.
Common brands: Flagyl and Flagyl ER; generic metronidazole tablets (250 mg, 500 mg) and capsules (375 mg); IV metronidazole infusion; topical metronidazole gel. Combination kits with bismuth and tetracycline for H. pylori infection regimens appear on some formularies.
Why we give it — Indications
Per FLAGYL (metronidazole) prescribing information, oral metronidazole treats susceptible anaerobic bacterial infections and certain protozoal infections. IV metronidazole is often started first for serious anaerobic infections, then stepped down to oral therapy when clinically appropriate.
| Use | Detail |
|---|---|
| Anaerobic bacterial infections | Intra-abdominal, skin/soft tissue, gynecologic, bone/joint (adjunct), CNS, lower respiratory, endocarditis, and septicemia caused by susceptible anaerobes (e.g., Bacteroides, Clostridium, Peptostreptococcus); surgical source control as indicated |
| Trichomonas vaginalis | Symptomatic and selected asymptomatic infection; treat sexual partners per protocol when organism confirmed |
| Amebiasis | Acute intestinal amebiasis and amebic liver abscess (does not replace drainage when indicated) |
| Antibiotic stewardship | Use only for proven or strongly suspected susceptible infections to limit resistance |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Metronidazole is a nitroimidazole that requires reduction in susceptible anaerobic bacteria to active forms that disrupt DNA synthesis. It has clinically relevant activity against many obligate anaerobes and Trichomonas vaginalis and Entamoeba histolytica; it does not treat facultative aerobes or viruses. Nursing relevance: the drug is not a substitute for source control in abscess or surgical infection, and alcohol or disulfiram co-exposure can cause severe reactions independent of antimicrobial effect.
Dosing overview
Doses below are from FLAGYL 375 capsules labeling; institutional protocols and IV product labeling may differ—always verify the active order and pharmacy renal/hepatic adjustments.
Hepatic and dialysis adjustments
Severe (Child-Pugh C) hepatic impairment: reduce amebiasis dose by 50% (375 mg q8h × 5–10 days); extend trichomoniasis interval to 375 mg q24h × 7 days. Hemodialysis removes metronidazole—consider supplemental dose after dialysis if the next scheduled dose cannot be separated from the session per labeling.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses. Follow prescriber and facility protocol.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Absorption (oral) | Similar disposition oral vs IV; food lowers peak and delays Tmax but not total exposure | May give with food if GI upset; alcohol restriction still applies |
| Half-life | ≈8 hours in healthy adults | Renal/hepatic impairment prolongs exposure—monitor adverse effects |
| Elimination | 60–80% urine; metabolites may accumulate in ESRD | Monitor for toxicity when renal function is poor |
| Dialysis | Hemodialysis removes 40–65% of dose per session | Coordinate timing and supplemental dosing with pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Allergy to metronidazole or other nitroimidazoles
- Alcohol use, mouthwash with alcohol, cooking wine, or products containing propylene glycol
- Disulfiram within the last two weeks
- Pregnancy trimester when used for trichomoniasis; Cockayne syndrome history
- Neurologic baseline and any numbness, ataxia, dizziness, or seizure history
- Complete medication reconciliation including topical and IV metronidazole duplicates
Contraindications
- Hypersensitivity to metronidazole or nitroimidazole derivatives
- Trichomoniasis in the first trimester of pregnancy
- Concurrent disulfiram or disulfiram within prior two weeks
- Cockayne syndrome (severe/fatal hepatotoxicity reported)
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Alcohol / propylene glycol | Disulfiram-like reaction (cramps, nausea, vomiting, headache, flushing) | Teach abstinence during therapy and ≥3 days after last dose; remove alcohol-based mouthwash from bedside |
| Disulfiram | Psychotic reactions reported with concurrent use | Hold metronidazole; verify last disulfiram dose |
| Warfarin / oral anticoagulants | Prolonged prothrombin time / INR | Monitor INR more frequently; notify prescriber/pharmacy |
| Lithium | Elevated serum lithium; toxicity signs possible | Check lithium and creatinine several days after starting metronidazole |
| Busulfan | Increased busulfan levels and toxicity risk | Pharmacy coordination; frequent monitoring if combination unavoidable |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Oral: May administer with or without food. Complete the full prescribed course unless hold criteria are met.
IV: Administer per pharmacy-prepared infusion rate and compatible fluids; document start/stop times on the MAR.
- Remove alcohol-containing mouthwash and educate visitors not to bring alcoholic beverages
- Separate administration timing from recent disulfiram per pharmacy guidance
- Flag new metallic taste, GI upset, or neuro symptoms for prescriber review
Labeling requires stopping alcoholic beverages and propylene glycol–containing products during therapy and for at least three days after the last dose. Hospital teams often miss alcohol-based mouthwash, elixirs, and hand sanitiser ingestion in confused patients—include these in admission teaching and MAR comments.
Expected therapeutic response
- Defervescence and clinical improvement in anaerobic infection when paired with appropriate source control
- Improving abdominal tenderness, wound drainage, or pelvic symptoms per primary team assessment
- Resolution of trichomoniasis symptoms and negative follow-up testing when ordered
- Stable neurologic exam without new numbness, ataxia, or seizure activity during therapy
Red flags — Stop and act
Hold metronidazole and escalate when:
- Disulfiram-like reaction after alcohol or propylene glycol exposure (severe abdominal pain, flushing, vomiting)
- New or worsening peripheral numbness, ataxia, dizziness, dysarthria, or confusion—possible encephalopathy or neuropathy
- Seizure, aseptic meningitis symptoms, or optic neuropathy signs
- Serious skin reaction (rash with fever, blistering, or mucosal involvement suggestive of TEN/SJS/DRESS)
- Signs of acute hepatotoxicity, especially in patients with Cockayne syndrome or unexplained liver failure after start
Adverse effects
| Adverse effect | Frequency / context | Nursing response |
|---|---|---|
| Nausea, vomiting, GI upset | Most common GI effects in labeling | Supportive care; differentiate from alcohol reaction or worsening infection |
| Metallic taste, furry tongue | Common; may see Candida overgrowth | Oral hygiene; treat candidiasis if symptomatic per prescriber |
| Peripheral neuropathy | Reported; may persist after prolonged courses | Stop drug and notify prescriber; document sensory changes |
| CNS toxicity (seizure, encephalopathy) | Serious; reversible in many cases after stop | Neuro assessment; hold drug; urgent prescriber escalation |
| QT prolongation | Reported, especially with other QT-prolonging drugs | Review electrolytes and interacting meds with pharmacy |
| Reversible neutropenia | Leukopenia observed in labeling | Consider CBC if prolonged therapy or infection not improving |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Single oral overdoses up to 15 g have been reported with nausea, vomiting, and ataxia. High intermittent doses (6–10.4 g every other day) in oncology protocols have been associated with seizures and peripheral neuropathy after 5–7 days per labeling.
Management
- No specific antidote—symptomatic and supportive therapy per clinical status
- Monitor neurologic status and GI symptoms; treat seizures per protocol
- Contact local poison control or medical toxicology services per facility protocol and local emergency guidance
Look-alike / sound-alike and error prevention
- Metronidazole vs metoclopramide, methotrexate, or metoprolol—verify generic name, dose, and indication
- Oral vs IV metronidazole—do not substitute routes without prescriber order
- Systemic vs topical metronidazole—topical gel is not appropriate for systemic anaerobic sepsis
- Alcohol-based mouthwash at bedside—common preventable interaction; stock alcohol-free oral care supplies
- Duplicate therapy—reconcile home Flagyl with inpatient MAR and perioperative orders
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Alcohol teaching | Post “no alcohol” sign on room board; include ≥3-day post-therapy abstinence in discharge instructions |
| Oral care | Replace alcohol mouthwash; expect metallic taste—still complete course unless held |
| Neuro checks | Ask about hand/feet numbness each shift on prolonged courses; trend in nursing notes |
| Anticoagulation | Extra INR checks when warfarin is home medication |
| Commonly missed | Visitor bringing beer; cologne/sanitiser ingestion in confusion; continuing after tingling fingers “because infection isn’t gone” |
| Ask pharmacy when | Hepatic dose adjustment, hemodialysis supplemental dose, lithium or busulfan co-therapy |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Hepatic impairment | Accumulation and adverse events more likely; severe Child-Pugh C requires dose/frequency reduction per labeling |
| End-stage renal disease | Metabolite accumulation—monitor for toxicity; dialysis dosing per pharmacy |
| Older adults | Higher active metabolite exposure; monitor closely for CNS and GI effects |
| Cockayne syndrome | Contraindicated—fatal hepatotoxicity reported |
| Pregnancy | Trichomoniasis: contraindicated first trimester; other uses require risk–benefit per prescriber. Adequate human pregnancy data limited in labeling. |
| Lactation | Present in breast milk at levels similar to maternal serum; labeling allows pump-and-discard during therapy and 48 h after last dose, or continue breastfeeding after risk–benefit discussion |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Neurologic exam (numbness, ataxia, dizziness, seizure activity) especially with prolonged or high-dose courses
- GI tolerance and signs of diarrhea or superinfection
- INR when patient takes warfarin or other oral anticoagulants
- Clinical response to infection (fever curve, wound, abdominal exam per team)
- Liver function tests and basic metabolic panel when hepatic or renal impairment is present or symptoms suggest toxicity
- Total and differential leukocyte counts before and after therapy when labeling recommends (blood dyscrasia precaution)
Document
- Alcohol/propylene glycol teaching provided and patient/visitor education
- Disulfiram history and hold actions
- Neurologic assessments and prescriber notifications for new symptoms
- Planned course end date and outpatient abstinence instructions (≥3 days post-therapy)
Patient teaching
- No alcohol and avoid products with propylene glycol during treatment and for at least three days after your last dose
- Finish the full antibiotic course even if you feel better—stopping early can fail treatment and promote resistance
- Report numbness or tingling in hands/feet, trouble walking, severe headache, vision changes, rash, or confusion immediately
- Metallic taste is common and usually temporary
- If you take warfarin, expect more frequent blood tests for clotting while on metronidazole
- Breastfeeding: discuss pump-and-discard options with your prescriber per labeling if infant exposure is a concern
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known hypersensitivity to metronidazole or nitroimidazoles
- Patient consumed alcohol or propylene glycol product and has active disulfiram-like symptoms
- Disulfiram used within the last two weeks
- First-trimester pregnancy with trichomoniasis indication
- Confirmed or suspected Cockayne syndrome
- New peripheral neuropathy symptoms, seizure, encephalopathy, or serious rash
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Metronidazole harm often comes from alcohol exposure and missed neurologic cues—not from wrong anaerobic coverage alone. Build alcohol abstinence and neuro screening into the medication pass.
1. Check-before-you-give protocol
- Right patient, drug, dose, route, and indication (systemic vs topical)
- Alcohol and propylene glycol exposure risk assessed this shift
- No disulfiram within two weeks; warfarin/lithium/busulfan flagged to pharmacy
- Quick neuro screen: numbness, gait, speech, new headache or rash
2. High-alert and safety badge
High interaction risk — alcohol abstinence & CNS monitoring requiredNot an ISMP high-alert medication for product mix-ups, but disulfiram-like reactions and irreversible neuropathy warrant interaction-focused safety workflows comparable to high-alert discipline.
3. Clinical workflow: hold and question rules
- Alcohol mouthwash on bedside table: remove, substitute alcohol-free care, document teaching
- Patient reports flushing after communion wine or cough syrup: hold, assess, notify prescriber
- Tingling fingers on day 5 of therapy: hold and request prescriber review before next dose
4. Critical teach-back questions
- “What must you avoid while taking metronidazole and for how long after?” (Patient should name alcohol and propylene glycol products and state at least three days after the last dose.)
- “What neurologic symptoms should you report right away?” (Patient should name numbness/tingling, trouble walking, severe headache, vision changes, or confusion.)
5. Care coordination
Pharmacist: Hepatic/renal adjustments, dialysis supplemental doses, warfarin/INR plan, lithium and busulfan interactions
Prescriber / ID or surgery team: Course duration, source control, and switch from IV to oral therapy
Infection prevention: Contact precautions and isolation when treating transmissible GI pathogens per facility policy—coordinate with the infection prevention team when indicated.
🧠 Quick mental checklist
- Has the patient had alcohol, propylene glycol products, or alcohol-based mouthwash this shift?
- Any disulfiram in the last two weeks?
- New numbness, ataxia, dizziness, or seizure activity since the last dose?
- Is warfarin on the chart—and when was INR last checked?
- Did I teach abstinence for three days after the last scheduled dose?
Metronidazole NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for metronidazole alcohol interaction and CNS safety using a tabbed inpatient case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), trend interpretation, documentation cloze, ordered response, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, history, and nursing note details for this case.
- Metronidazole 500 mg IV q8h — 1400 dose given; next due 2200
- Metronidazole 500 mg PO ordered to start tomorrow when tolerating diet
- Piperacillin-tazobactam IV per protocol — 0600 dose given
- Warfarin 5 mg PO daily — held this morning per pharmacy (INR elevated)
- INR today: 3.8 (goal 2–3); on warfarin for mechanical valve
- AST 42 U/L; ALT 38 U/L; bilirubin WNL
- Creatinine 1.0 mg/dL; eGFR 82 mL/min/1.73 m²
- WBC trending down; temp 37.4 °C
- Admits to one beer yesterday with dinner before surgery
- Home medications include warfarin; no disulfiram on reconciliation
- Visitor brought alcohol-based mouthwash “for fresh breath” — on overbed table
- Denies illicit drugs; drinks socially on weekends
- 58-year-old post laparotomy for intra-abdominal abscess; day 4 IV antibiotics
- 1800: reports metallic taste, mild nausea, and tingling in fingertips started today
- Flushed face noted after visitor helped with mouthwash at 1730
- Patient ambulating with steady gait; denies dizziness now
Answer key & rationale
Frequently asked questions
How long must patients avoid alcohol with metronidazole?
FLAGYL prescribing information requires stopping alcoholic beverages and products containing propylene glycol during therapy and for at least three days afterward because a disulfiram-like reaction may occur.
When should a nurse hold metronidazole?
Hold for hypersensitivity, alcohol or propylene glycol exposure with active reaction symptoms, disulfiram within the last two weeks, first-trimester trichomoniasis, Cockayne syndrome, new neurologic symptoms, or serious rash. Coordinate hepatic and dialysis adjustments with pharmacy.
What neurologic adverse effects require immediate action?
Labeling reports seizures, encephalopathy, peripheral neuropathy, and aseptic meningitis. Patients should stop the drug and report numbness, ataxia, or confusion immediately; abnormal neurologic signs require urgent prescriber review.
Is there an antidote for metronidazole overdose?
No specific antidote is listed in prescribing information. Management is symptomatic and supportive. Contact local poison control or medical toxicology services per facility protocol.
Can metronidazole be used during breastfeeding?
Metronidazole is present in human milk at concentrations similar to maternal serum. Labeling allows pump-and-discard during therapy and for 48 hours after the last dose, or breastfeeding after individualized risk–benefit discussion with the prescriber.
References
-
U.S. National Library of Medicine. FLAGYL (metronidazole) capsules — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2883ca1-5a9a-4259-9d80-46ab67274384
-
Drugs and Lactation Database (LactMed). Metronidazole. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/NBK470418/
-
U.S. National Library of Medicine. Metronidazole — MedlinePlus drug information.https://medlineplus.gov/druginfo/meds/a682711.html
-
U.S. Food and Drug Administration. FDA drug safety communication: antibacterial drugs and the risk of serious skin reactions.https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-serious-skin-reactions-certain-antibiotics
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.